RRM2 Alleviates Doxorubicin-Induced Cardiotoxicity through the AKT/mTOR Signaling Pathway

RRM2 Alleviates Doxorubicin-Induced Cardiotoxicity through the AKT/mTOR Signaling Pathway

Doxorubicin (DOX) is an effective chemotherapeutic agent that plays an unparalleled role in cancer treatment. However, its serious dose-dependent cardiotoxicity, which eventually contributes to irreversible heart failure, has greatly limited the widespread clinical application of DOX. A previous stu...

Full description

Bibliographic Details
Main Authors: Yuheng Jiao, Yanyan Li, Jiayan Zhang, Song Zhang, Yafang Zha, Jian Wang
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Biomolecules
Subjects:
RRM2
doxorubicin
AKT/mTOR pathway
cardiotoxicity
Online Access:https://www.mdpi.com/2218-273X/12/2/299

Similar Items

Similar Items